Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 130 publications.

Ray KK, Bardet A, Komen J, Manga N, Wolowacz S, Bregantini D, Becker C, Catapano AL. Simulation of long-term impact of bempedoic acid and ezetimibe on atherosclerotic cardiovascular disease outcomes in Europe. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Buck P, Sweeney C, Georgieva M, Kunzweiler C, Tossonian H, Boyle K, Chirila C, Crawford R, Wolowacz S, Pesch M. Family spillover impact of congenital CMV in the United States and Canada: study methodology. Poster presented at the European Congenital Cytomegalovirus Initiative (ECCI) 2024; October 9, 2024. Leiden, the Netherlands.

Wolowacz S, Lloyd A, Doward L, Hawe E. Estimating health-state utility for economic models in clinical trials and real-world studies. Presented at the ISPOR 2024; May 5, 2024. Atlanta, GA.

Sawant R, Paret K, Petrillo J, Koenig A, Wolowacz S, Ronquest N, Rickards H. Health state utility estimates for value assessments of novel treatments in Huntington's disease: a systematic literature review. Health Qual Life Outcomes. 2024 Apr 16;22(1):33. doi: 10.1186/s12955-024-02242-1

Hohmann C, Manga N, Wolowacz S, Bregantini D, Pfister R. Impact of bempedoic acid on CV outcomes and costs in Germany. Poster presented at the 130th Congress of the German Society of Internal Medicine; April 13, 2024. Wiesbaden, Germany.

Doward L, Hawe E, Lloyd A, Wolowacz S. Estimating health-state utility for economic models in clinical trials and real-world studies. Presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark.

Toplak H, Bilitou A, Alber H, Auer J, Clodi M, Ebenbichler C, FlieBer-Gorzer E, Gelsinger C, Hanusch U, Ludvik B, Maca T, Schober A, Sock R, Speidl WS, Stulnig TM, Weitgasser R, Zirlik A, Koch M, Wienerroither S, Wolowacz SE, Diamand F, Catapano AL. Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients. Wein Klin Wochenschr. 2023 Jul;135(13-14):364-74. doi: 10.1007/s00508-023-02221-4

Grace M, Costello J, Colosia A, Wolowacz S, Ghaswalla P, Panozzo CA, Moore P. Economic and HRQoL burden in adults with RSV: a systematic literature review. Poster presented at the Communicable Diseases & Immunisation Conference 2023; June 20, 2023. Perth, Australia. Previously presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW).

Dong O, Manga N, Zhong Y, Zhang Y, Krause T, Griffin J, Herring WL, Wolowacz S. Use of patient-reported outcomes as key drivers in cost-effectiveness models: a review of UK National Institute for Health and Care Excellence health technology assessments. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S78. doi: 10.1016/j.jval.2023.03.405

Katzmann JL, Laufs U, Diamand F, Wolowacz S, Becker C, Bilitou A. Addition of bempedoic acid to the lipid-lowering treatment pathway for high and very high-risk patients in Germany: a simulation study using the SANTORINI observational study cohort. Poster presented at the DGK 89th Annual Meeting; April 13, 2023. Mannheim, Germany.

Grace M, Costello J, Colosia A, Wolowacz S, Panozzo CA, Ghaswalla P. Economic and health-related quality of life burden in adults with RSV: a systematic literature review and gap analysis. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.

Grace M, Colosia A, Wolowacz S, Panozzo C, Ghaswalla P. Economic burden of respiratory syncytial virus infection in adults: a systematic literature review. J Med Econ. 2023;26(1):742-59. doi: 10.1080/13696998.2023.2213125

Yucel E, Hartley L, Bell J, Wolowacz S, Kamgar F, Hawe E. A systematic literature review of utility estimates for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S395. doi: 10.1016/j.jval.2022.09.1964

Herring WL, Gould IG, Wittrup-Jensen V, Ertle J, Kuti E, Wolowacz S. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes. J Comp Eff Res. 2022 Dec 1;11(18):1349-63. doi: 10.2217/cer-2021-0194

Wolowacz S, Bhatnagar V, Vickers A, Pickaert AP. Clinical evidence for health technology assessment in oncology, are we going backwards? Where are we going with single-arm trials? Presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria.

Wolowacz S. Incorporating informal care considerations in HTA. Presented at the ISPOR Europe 2022; November 7, 2022.

Petrillo J, Paret K, Sawant R, Koenig A, Wolowacz S, Ronquest N, Rickards H. Estimation of health state utilities in Huntington's disease: a targeted review. Poster presented at the HSG 2022 Annual Meeting; November 2022. Tampa, FL. [abstract] J Huntingtons Dis. 2022 Oct 31; 11(s1):S31. Previously presented at the European Huntington's Disease Network (EHDN) 2022 Plenary Meeting. doi: 10.3233/JHD-229005

Petrillo J, Paret K, Sawant R, Koenig A, Wolowacz S, Ronquest N, Rickards H. Estimation of health state utilities in Huntington's disease: a targeted review. Poster presented at the European Huntington's Disease Network (EHDN) 2022 Plenary Meeting; September 18, 2022. Bologna, Italy. [abstract] J Neurol Neurosurg Psychiatry. 2022 Sep 12; 93(suppl 1):A45-6. doi: 10.1136/jnnp-2022-ehdn.118

Ray KK, Catapano AL, Diamand F, Wolowacz S, Haq I, Bilitou A. Simulation of bempedoic acid in the lipid-lowering treatment pathway using the European contemporary SANTORINI cohort of high- and very high-risk patients. Poster presented at the European Society of Cardiology Congress 2022; August 26, 2022. Barcelona, Spain.

Hawe E, Meleth S, Wolowacz S, Bilitou A. Importance of baseline LDL-C in the association between LDL-C lowering and cardiovascular risk: a meta-regression analysis. Poster presented at the 90th EAS Congress; May 22, 2022. Milan, Italy. [abstract] Atherosclerosis. 2022 Aug; 355:184-5. doi: 10.1016/j.atherosclerosis.2022.06.760

Whalley D, Belongie K, Frangiosa T, Krasa H, Mladsi DM, Twiss J, Wolowacz S. Understanding the patient experience of erythropoietic protoporphyria and x-linked protoporphyria: a qualitative study. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Bego G, Tavi J, Wang Z, Kuznik A, Brignoli L, Mnif T, Wolowacz S, Jia X. Quality of life of caregivers of pediatric patients with atopic dermatitis: a quantitative assessment of utilities from EQ-5D. Poster presented at the Virtual ISPOR Europe 2021; November 30, 2021. [abstract] Value Health. 2022 Jan; 25(1, Supplement):S101. doi: 10.1016/j.jval.2021.11.480

Jen MH, Sonksen M, Kiiskinen U, Wolowacz S, Vickers AD, Hawe E. Surrogate outcomes for overall survival in pretreated non-small cell lung cancer: expanding the prediction range. Poster presented at the Virtual ISPOR Europe 2021; December 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

Aronsson M, Dunton K, Hawe E, Wolowacz S, Quoraishi S, Durrington P, Ray KK, Bilitou A. Building a cost-effectiveness MODEL framework from a payer's perspective to assess NOVEL treatments in primary hypercholesterolaemia and MIXED dyslipidaemia: challenges in a world of LDL-C lowering. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).

Herring WL, Gould IG, Wittrup-Jensen V, Kuti E, Mettam S, Ertle J, Wolowacz S. A conceptual model for the economic evaluation of emerging nonalcoholic steatohepatitis therapies: the impact of treatment efficacy profiles on health outcomes. Poster presented at the 2020 SMDM 18th Biennial European Conference (Conference cancelled); June 16, 2020.

Bego-Le Bagousse G, Jia X, Wolowacz S, Eckert L, Tavi J, Hudson R. Health utility estimation in children and adolescents: a review of health technology assessments. Curr Med Res Opin. 2020 May 22;29(1). doi: 10.1080/03007995.2020.1762553

Cawson M, Wolowacz S, Doward L, Sinha A. Health utility estimates for congenital cytomegalovirus disease: conceptual design considerations. Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Brazier JE, Knight H, Wolowacz SE. Including caregiver / family member quality of life in economic evaluations – your questions answered. Presented at the ISPOR 2019 European Conference; November 6, 2019. Copenhagen, Denmark.

Wolowacz SE, Benedict A, Kamal K. Improving the availability and quality of utility estimates for the post-progression period in oncology models: recommendations based on a systematic review. Presented at the 2019 ISPOR 24th Annual International Meeting; May 20, 2019. New Orleans, LA.

Basarir H, Brockbank J, Knight C, Wolowacz S. The inclusion of the utility values for carers and family members in HTAs: a case study of recent NICE appraisals in the UK. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 22, 2019. New Orleans, LA. [abstract] Value in Health Regional Issues. 2019 May; 22(Suppl 2):S330.

Masaquel C, Rothwell B, Bhaila R, Copley-Merriman C, Wolowacz S, Aguiar-Ibanez R, Patel N, Liu FX. A systematic review of utility estimates in melanoma in the adjuvant setting. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain.

Wolowacz SE, Briggs A, Doward L, Lloyd A. Collecting health-state utility estimates for economic models in clinical studies. Presented at the 2018 ISPOR 21st Annual European Congress; November 10, 2018. Barcelona, Spain.

Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Chirila C, Hollis K, Sweeney C, Price M, Wolowacz S, Kaye JA, Kontoudis I. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: a retrospective observational study (LuCaBIS). Lung Cancer. 2018 Oct;124:298-309. doi: 10.1016/j.lungcan.2018.06.007

Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Price M, Chirila C, Hollis K, Sweeney C, Wolowacz S, Kaye JA, Kontoudis I. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. Lung Cancer. 2018 Oct;124:310-6. doi: 10.1016/j.lungcan.2018.07.042.

Zuluaga-Sanchez S, Hess LM, Wolowacz SE, D'yachkova Y, Hawe E, Vickers AD, Kaye JA, Bertwistle D. Cost-effectiveness of olaratumab in combination with doxorubicin for patients with soft tissue sarcoma in the United States. Sarcoma. 2018 Mar 26;2018:6703963. doi: 10.1155/2018/6703963

Grange F, Mohr P, Harries M, Ehness R, Benjamin L, Siakpere O, Barth J, Stapelkamp C, Pfersch S, McLeod LD, Kaye JA, Wolowacz S, Kontoudis I. Economic burden of advanced melanoma in France, Germany, and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study). Melanoma Res. 2017 Dec;27(6):607-18. doi: 10.1097/CMR.0000000000000372

Wolowacz S, Briggs A, Lloyd A, Doward L. Collecting health-state utility estimates for economic models in clinical studies. Presented at the 2017 ISPOR 20th Annual European Congress; November 4, 2017. Glasgow, Scotland. Previously presented at the ISPOR 19th Annual European Congress.

Wolowacz S, Mauskopf J, Earnshaw SR. Determining the analytic framework. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.11-34. doi: 10.1007/978-3-319-50482-7

Wolowacz S, Mauskopf J, Earnshaw SR. Estimating condition-related costs. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.91-101. doi: 10.1007/978-3-319-50482-7

Mauskopf J, Wolowacz S, Earnshaw SR. Alternative interventions. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.203-16. doi: 10.1007/978-3-319-50482-7

Muszbek N, Benedict A, Wolowacz S. Health economic modeling in oncology. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. Previously presented at the ISPOR 19th Annual European Congress.

Wolowacz S, Briggs A, Lloyd AJ, Doward L. Collecting health-state utility estimates for economic models in clinical studies. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 21, 2017. Boston, MA. Previously presented at the ISPOR 19th Annual European Congress.

Harries M, Mohr P, Grange F, Ehness R, Benjamin L, Siakpere O, Barth J, Stapelkamp C, Pfersch S, McLeod L, Wolowacz S, Kaye JA, Kontoudis I. Treatment patterns and outcomes of Stage IIIB/IIIC melanoma in France, Germany and the UK: a retrospective and prospective observational study (MELABIS). Int J Clin Pract. 2017 May 16;71(5):e12946. doi: 10.1111/ijcp.12946

Brockbank J, Wolowacz S. Economic evaluations of new oral anticoagulants for the prevention of venous thromboembolism after total hip or knee replacement: a systematic review. Pharmacoeconomics. 2017 May;35(5):517-35. doi: 10.1007/s40273-017-0486-4

Zuluaga S, Hess LM, Wolowacz S, Dyachkova Y, Hawe E, Vickers AD, Kaye JA, Bertwistle D. Cost-effectiveness of olaratumab in combination with doxorubicin for the treatment of locally advanced or metastatic soft tissue sarcoma in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A108.

Wolowacz S. Editorial: ISPOR good research practices task force report—mapping to estimate utility values from non–preference-based outcome measures. Value Health. 2017 Jan;20(1):28-9. doi: 10.1016/j.jval.2016.11.026

Wolowacz S. New ISPOR recommendations - mapping methods for estimation of health state utility. Value Health. 2017 Jan;20(1):28-9. doi: 10.1016/j.jval.2016.11.026

Bertwistle D, D'yachkova Y, Vickers AD, Hawe E, Fernandez M, Drove N, Lorenzo M, Wolowacz S. Comparative efficacy and saftey of interventions in the treatment of advanced soft tissue sarcoma: a systematic review and network meta analysis. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A712.

Boysen M, Tyas D, Ling C, Wolowacz S. The new NICE cancer drugs fund technology appraisal process: your questions answered. Presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria.

Muszbek N, Wolowacz S, Benedict A. Health economic modeling in oncology. Presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria.